RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between TriviumVet and the amazing teams at UC Davis and North Carolina State University with the support of Argenta Global, we are thrilled that Dr Josh Stern will tomorrow present a first look at the positive findings from RAPACAT at the International Cardio-Renal Veterinary Symposium (ICVS) 2022, hosted by Boehringer Ingelheim in Berlin.
RAPACAT was a randomized, double-blind, placebo-controlled, clinical trial in client-owned cats with HCM. Under the care of board-certified cardiologists, enrolled cats were followed for a 6-month treatment period, during which time they underwent repeat examinations, blood tests, and echocardiography while receiving our novel, patented Rapamycin formulation, specifically formulated for cats. The results are exciting!
For anyone not attending ICVS in Berlin, there’s another chance to hear Dr Stern speak at the sister event in Fort Lauderdale, FL, in 2 weeks’ time – October 14th to 16th.